Skip to main content
. 2019 Mar-Apr;94(2 Suppl 1):76–107. doi: 10.1590/abd1806-4841.2019940211

Table 3.

Evaluation of infliximab expressed by the benefit estimated in percentage

Author Dose Time of follow-up PASI 50 (%) PASI 75 (%) PASI 90 (%) PGA (%) DLQI (%)
Feldman ST (148) 3mg/kg 10 weeks       8.9
Feldman ST (148) 5mg/kg 10 weeks       9.9
Reich K (12) 5mg/kg 10 weeks 79.6 55.8   9.9
Gottlieb AB (6) 3mg/kg 10 weeks 62.2 65.8 45.5 61.9  
Gottlieb AB (6) 5mg/kg 10 weeks 75.4 82 55.6 80.1  
Chaudhari U (146) 5mg/kg 10 weeks 63.6      
Chaudhari U (146) 10mg/kg 10 weeks 54.5